Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c‐Kit‐Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT‐HF Clinical Trial | Synapse
April 22, 2026Journal of the American Heart Association0 citationsOpen Access
Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c‐Kit‐Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT‐HF Clinical Trial
The aim is to evaluate the impact of autologous mesenchymal stromal cells and c-kit-positive cardiac cells on circulating biomarkers in ischemic heart failure.
Conducted a clinical trial (CONCERT-HF) comparing effects of different cell therapies.
Analyzed circulating biomarkers before and after treatment.
Evaluated both monotherapy and combination therapy with cells.
Treatment with mesenchymal stromal cells and c-kit-positive cells leads to significant changes in biomarker levels.
Combination therapy shows enhanced effects compared to individual treatments.
Results suggest improved patient outcomes through biomarker modulation.